Glucagon

How does it work?

Carepatron’s Glucagon Test template streamlines the assessment process with clear, clinically relevant steps. Whether you’re screening for glucagonoma or investigating hypoglycemia, the template helps ensure consistent documentation, proper sample handling, and accurate interpretation, right from your workflow. Here’s how to put it to use in your clinical setting.

Step 1: Access the template

Click “Use template” to launch Carepatron’s secure platform. You’ll be guided to download the app if you haven’t already. The template will open automatically, giving you instant access to structured clinical fields designed to align with lab protocols and streamline your assessment workflow. This includes fields for CPT codes, test ID, and logical observation identifiers names.

Step 2: Use the template in patient assessment

Follow each built-in step to properly collect and handle the specimen. The template includes reminders for tube selection, pre-chilling, centrifugation, and plasma freezing—minimizing the risk of pre-analytical errors. Use it as a checklist during specimen collection to ensure every requirement is met when you draw blood, prevent gross hemolysis, and ensure a viable blood sample.

Step 3: Conduct the assessment

Once results are returned from the lab, input and review them directly in the template. Built-in interpretation guidance helps contextualize glucagon levels alongside other lab markers such as insulin and glucose, supporting clearer diagnostic decisions and improved clinical communication. You can assess blood glucose, blood sugar level, and normal range values all in one view.

Step 4: Gather and interpret results

Once results are returned from the lab, input and review them directly in the template. Built-in interpretation guidance helps contextualize glucagon levels alongside other lab markers such as insulin and glucose, supporting clearer diagnostic decisions and improved clinical communication.

Step 5: Provide next steps and patient support

Document follow-up recommendations and patient education in the designated section. Whether initiating treatment, ordering imaging, or referring to endocrinology, Carepatron lets you maintain clear, shareable notes—keeping your care team aligned and your patients fully informed.

When would you use this test?

The Glucagon Test, also known as the glucagon stimulation test, is a valuable tool for various healthcare practitioners, especially endocrinologists and diabetologists, as it helps diagnose and manage multiple conditions related to glucose metabolism. Here are vital scenarios and clinical situations in which the Glucagon Test is used:

• Diagnosis of insulinoma: Insulinoma is a rare pancreatic tumor that causes excess insulin production, leading to hypoglycemia (low blood sugar). The Glucagon Test confirms this condition by assessing how the patient's blood sugar responds to a glucagon injection. In cases of insulinoma, there is an exaggerated insulin response.
• Evaluation of hypoglycemia: The test is crucial for investigating unexplained and recurrent episodes of hypoglycemia. It helps practitioners differentiate between fasting hypoglycemia and reactive hypoglycemia, providing insights into the underlying cause.
• Monitoring diabetes management: In managing diabetes, especially type 1 diabetes, the Glucagon Test can be used to evaluate the ability of the pancreas to produce glucagon in response to low blood sugar. This information can guide insulin dosing and dietary recommendations.
• Assessment of congenital hyperinsulinism: This rare genetic disorder in infants and children produces excessive insulin, resulting in severe hypoglycemia. The Glucagon Test can aid in confirming the diagnosis and planning treatment strategies.
• Pancreatic function assessment: It can assess pancreatic function, particularly the alpha cells in the islets of Langerhans, which produce glucagon. This is crucial in understanding the overall health of the pancreas and its contribution to glucose homeostasis.
• Research and clinical trials: Researchers studying glucose metabolism and related disorders employ the Glucagon Test as a standardized procedure to evaluate the effects of various medications or interventions on blood sugar regulation.

What do the results mean?

Interpreting the results of a Glucagon Test is essential for diagnosing and managing various conditions related to glucose metabolism. Common results and their meanings include:

• Normal response: A Glucagon Test typically triggers a normal response in a healthy individual. This means that when synthetic glucagon is administered, the blood sugar levels will increase as expected. This indicates that the pancreas functions correctly regarding glucagon secretion and the liver's response.
• Blunted Response: A blunted response may indicate dysfunction in the pancreas, particularly the alpha cells responsible for producing glucagon. This can be seen in individuals with diabetes, especially type 2 diabetes, where the pancreas may not have adequate glucagon in response to low blood sugar. It can also be observed in people with chronic liver disease.
• Exaggerated response: An exaggerated response to the Glucagon Test can be a sign of overactivity of the alpha cells in the pancreas. This is often seen in cases of insulinoma, a rare pancreatic tumor that leads to excessive glucagon secretion and hypoglycemia.
• Reactive hypoglycemia: For individuals experiencing reactive hypoglycemia, the test may show a sharp drop in blood sugar followed by a quick rebound to higher levels. This indicates that their body releases too much insulin in response to a meal, causing a reactive drop in blood sugar.
• Congenital hyperinsulinism: In cases of congenital hyperinsulinism, a condition often found in infants, the test may reveal a lack of appropriate response to glucagon. This suggests that the pancreas is producing excess insulin and not responding appropriately to glucagon, leading to severe hypoglycemia.
• Research context: In a research setting, the Glucagon Test can yield a range of results, depending on the study's specific objectives. Researchers use the results to understand the effects of different interventions or medications on blood sugar regulation.

Research & evidence

The Glucagon Test has a history rooted in understanding glucose metabolism and the role of hormones produced by the pancreas (Rix et. al., 2019). 

The study of glucagon and its function began in the early 20th century when researchers discovered a pancreatic factor responsible for elevating blood sugar levels (Hædersdal et. al., 2018). In 1953, Dr. Roger Unger, a renowned endocrinologist, isolated and characterized glucagon as a hormone produced by the pancreas, specifically by the alpha cells in the islets of Langerhans (Unger & Cherrington, 2012).

Research in the following decades shed light on the importance of glucagon in maintaining glucose homeostasis, acting in opposition to insulin by promoting the release of stored glucose from the liver into the bloodstream (Nakrani et. al., 2023).

The glucagon stimulation test was developed as a diagnostic tool in the latter half of the 20th century (Cuboni et. al., 2024). It assessed pancreatic function and the body's response to low blood sugar conditions, often associated with diseases like insulinoma, hypoglycemia, and diabetes. 

The test was refined and standardized to measure the body's reaction to synthetic glucagon, allowing healthcare practitioners to evaluate pancreatic function accurately.

Over the years, numerous clinical studies and trials have used the Glucagon Test to investigate and diagnose various disorders related to glucose metabolism (Kawamori & Sasaki, 2023). Evidence from these studies has demonstrated the test's effectiveness in diagnosing conditions such as insulinoma, hypoglycemia, and congenital hyperinsulinism and assessing pancreatic function in diabetes.

The Glucagon Test remains a fundamental tool in endocrinology and diabetes care, providing insights into pancreatic function and aiding in personalized treatment plans.

References

Cuboni, D., Caputo, M., Ghigo, E., Aimaretti, G., & Gasco, V. (2024). Once upon a time: The glucagon stimulation test in diagnosing adult GH deficiency. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02322-5

Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018). The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clinic Proceedings, 93(2), 217–239. https://doi.org/10.1016/j.mayocp.2017.12.003

Kawamori, D., & Sasaki, S. (2023). Newly discovered knowledge pertaining to glucagon and its clinical applications. Journal of Diabetes Investigation, 14(7), 829–837. https://doi.org/10.1111/jdi.14009

Nakrani, M. N., Wineland, R. H., & Anjum, F. (2023, July 17). Physiology, glucose metabolism. PubMed. https://www.ncbi.nlm.nih.gov/books/NBK560599/

Rix, I., Nexøe-Larsen, C., Bergmann, N. C., Lund, A., & Knop, F. K. (2019, July 16). Glucagon physiology. National Library of Medicine; MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279127/

Unger, R. H., & Cherrington, A. D. (2012). Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. Journal of Clinical Investigation, 122(1), 4–12. https://doi.org/10.1172/jci60016